No abstract available
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adenine / analogs & derivatives
-
Agammaglobulinaemia Tyrosine Kinase / genetics
-
Antineoplastic Agents / pharmacology
-
Biomarkers, Tumor / genetics
-
CD79 Antigens / genetics
-
Cell Line, Tumor
-
Class I Phosphatidylinositol 3-Kinases / genetics
-
Gene Expression Profiling*
-
Gene Expression Regulation, Neoplastic
-
Humans
-
Immunotherapy
-
Leukocytes, Mononuclear / cytology
-
Lymphoma, Mantle-Cell / drug therapy
-
Lymphoma, Mantle-Cell / genetics*
-
Neoplasm Recurrence, Local
-
Piperidines
-
Prognosis
-
Progression-Free Survival
-
Proto-Oncogene Proteins c-akt / genetics
-
Proto-Oncogene Proteins c-bcl-2 / genetics
-
Pyrazoles / pharmacology*
-
Pyrimidines / pharmacology*
-
Randomized Controlled Trials as Topic
-
Receptors, Antigen, B-Cell / genetics*
-
Recurrence
-
Stem Cell Transplantation
-
Syk Kinase / genetics
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
BCL2 protein, human
-
Biomarkers, Tumor
-
CD79 Antigens
-
CD79B protein, human
-
Piperidines
-
Proto-Oncogene Proteins c-bcl-2
-
Pyrazoles
-
Pyrimidines
-
Receptors, Antigen, B-Cell
-
ibrutinib
-
Class I Phosphatidylinositol 3-Kinases
-
PIK3CD protein, human
-
Agammaglobulinaemia Tyrosine Kinase
-
BTK protein, human
-
SYK protein, human
-
Syk Kinase
-
AKT3 protein, human
-
Proto-Oncogene Proteins c-akt
-
Adenine